Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2025, quý kết thúc ngày Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Adaptimmune Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2025 was $125.24M, down 14.6% year over year. For fiscal 2024 it was $149.06M, up 17.8% from the year before. The highest annual figure on record is $149.06M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $149.06M | +17.8% |
| FY2023 | Dec 31, 2023 | $126.51M | -1.0% |
| FY2022 | Dec 31, 2022 | $127.73M | +15.0% |
| FY2021 | Dec 31, 2021 | $111.09M | +21.3% |
| FY2020 | Dec 31, 2020 | $91.57M | -6.1% |
| FY2019 | Dec 31, 2019 | $97.50M | -0.8% |
| FY2018 | Dec 31, 2018 | $98.27M | +12.5% |
| FY2017 | Dec 31, 2017 | $87.39M | +262.0% |
| FY2015 | Jun 30, 2015 | $24.14M | +152.1% |
| FY2014 | Jun 30, 2014 | $9.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $22.98M | -43.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $28.86M | -18.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $39.10M | +17.7% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $34.30M | -9.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $40.45M | +35.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $35.21M | +37.8% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $33.21M | +44.1% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $37.79M | +13.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $29.97M | -13.7% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $25.55M | -30.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $23.05M | -21.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $33.18M | +17.6% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $34.74M | +20.3% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $36.75M | +50.0% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $29.51M | +14.5% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $28.21M | +17.2% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $28.87M | +41.1% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $24.51M | +15.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $25.78M | +26.6% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $24.07M | -18.7% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $20.46M | -19.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $21.26M | -3.4% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $20.35M | -10.6% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $29.62M | +26.1% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $25.51M | -4.2% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $22.02M | -14.4% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $22.77M | -9.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $23.48M | -2.3% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $26.62M | +35.9% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $25.73M | +38.2% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $25.15M | +199.2% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $24.03M | +302.2% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $19.59M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $18.62M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $8.40M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $5.98M | – |
See a number that looks wrong?